Stay updated on Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe site version badge updated from v3.4.1 to v3.4.2, indicating a backend/frontend revision. No study content or functionality was changed as part of this update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check21 days agoChange DetectedThe only visible change is the footer revision updated from v3.4.0 to v3.4.1, and the main content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check36 days agoChange DetectedThe label in the Study Dates section changed from 'Last Update Posted (Estimated)' to 'Last Update Posted' to clarify the timestamp shown.SummaryDifference0.1%

- Check43 days agoChange DetectedRevision history shows the addition of Revision: v3.3.4 and the removal of Revision: v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check64 days agoChange DetectedA dedicated Locations section now lists Pennsylvania as the study site, replacing the prior Pennsylvania Locations entry. The footer's HHS Vulnerability Disclosure was removed and the revision updated to v3.3.3.SummaryDifference0.3%

- Check93 days agoChange DetectedRevision tag updated from v3.2.0 to v3.3.2; no study information or eligibility details appear to be altered.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Post-Tx in Oligometastatic NSCLC Clinical Trial page.